Checkpoint Therapeutics Submits Biologics License Application for Skin Cancer Therapy
MT NEWSWIRES
11:27 AM ET 01/04/2023
11:27 AM EST, 01/04/2023 (MT Newswires) -- Checkpoint Therapeutics (CKPT) said Wednesday it has submitted a biologics license application to the US Food and Drug Administration for the approval of cosibelimab to treat patients with metastatic cutaneous squamous cell carcinoma or locally advanced cSCC who are not candidates for curative surgery or radiation.
The application is backed by positive efficacy and safety data from its ongoing trial of cosibelimab, the company said.
Shares of Checkpoint Therapeutics (CKPT) rose more than 6% in recent trading activity.
Market Data 
Markets 
AI
